Return to TA329 Overview

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy [TA329]

Measuring the use of this guidance

Recommendation: 1.1

Infliximab, adalimumab and golimumab are recommended, within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.

What was measured: Proportion of adult patients on biological therapy who were appropriately prescribed anti-TNFα therapy in compliance with NICE technology appraisal 329 for treating moderately to severely active ulcerative colitis.
Data collection end: March 2014
82%
Number that met the criteria: 262 / 318
Data collection end: February 2016
74%
Number that met the criteria: 293 / 395
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.


Recommendation: 1.3

Infliximab is recommended, within its marketing authorisation, as an option for treating severely active ulcerative colitis in children and young people aged 6–17 years whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.

What was measured: Proportion of paediatric patients on biological therapy who were appropriately prescribed anti-TNFα therapy in compliance with NICE technology appraisal 329 for treating moderately to severely active ulcerative colitis.
Data collection end: March 2014
40%
Number that met the criteria: 26 / 65
Data collection end: February 2016
27%
Number that met the criteria: 7 / 26
Area covered: National
Source: Royal College of Physicians. National Clinical Audit of Biological therapies: UK Inflammatory Bowel Disease Audit.



 Return to TA329 Overview